CEO Buys 12,200 Shares of Anika Therapeutics, Boosting Investor Optimism
CEO’s $12.29 buy of 12,200 shares signals confidence in Anika Therapeutics’ turnaround—boosts sentiment, hints at future growth from new mCRPC and HER2‑targeted drugs, and could spark a valuation rebound.
3 minutes to read